Literature DB >> 1382047

Reoxygenation in the RIF-1 tumor after chemotherapy.

M J Dorie1, R F Kallman.   

Abstract

The proportion of hypoxic cells in the RIF-1 tumor was observed for 24 hr after treatments with bleomycin, cisplatin, cyclophosphamide, and mitomycin C. The assays were based upon the paired survival curve method for determining the hypoxic fraction using irradiation of aerobic and artificially hypoxic tumors. It was observed that at 1/2 hr after bleomycin, hypoxic fraction was elevated but returned to baseline levels by 2 hr. Following cisplatin, hypoxic fraction did not rise above baseline. However, after cyclophosphamide, hypoxic fraction was elevated and did not return to baseline over the 24-hr observation period of this study. At 1/2 hr after mitomycin treatment, the hypoxic fraction was raised but within 1 hr returned to baseline. These results indicate that tumor reoxygenation varies after different drug treatments and that the determination of drug specificity for aerobic versus hypoxic cells may be strongly biased by the choice of the time after treatment for making the determination.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382047     DOI: 10.1016/0360-3016(92)90684-a

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  3 in total

1.  TH-302, a hypoxia-activated prodrug with broad in vivo preclinical combination therapy efficacy: optimization of dosing regimens and schedules.

Authors:  Qian Liu; Jessica D Sun; Jingli Wang; Dharmendra Ahluwalia; Amanda F Baker; Lee D Cranmer; Damien Ferraro; Yan Wang; Jian-Xin Duan; W Steve Ammons; John G Curd; Mark D Matteucci; Charles P Hart
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-02       Impact factor: 3.333

2.  Letter in response to paper by Abratt et al., Cancer Chemother Pharmacol (1992) 30: 495.

Authors:  S Senan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

3.  Efficacy and safety of the hypoxia-activated prodrug TH-302 in combination with gemcitabine and nab-paclitaxel in human tumor xenograft models of pancreatic cancer.

Authors:  Jessica D Sun; Qian Liu; Dharmendra Ahluwalia; Wenwu Li; Fanying Meng; Yan Wang; Deepthi Bhupathi; Ayesha S Ruprell; Charles P Hart
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.